Novo Nordisk's semaglutide shows improved mental and physical wellbeing as obesity treatment
New data suggests that Novo Nordisk's molecule semaglutide improves the mental and physical wellbeing of obesity patients according to results from the pharmaceutical company's Step program.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
A weekly dose of Novo Nordisk's semaglutide as a treatment for obesity seems to result in weight loss as well as improved physical function and psychological wellbeing, according to results from the Danish pharmaceutical firm's phase IIIa known as Step 1.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk expands obesity business in spite of obstacles
For subscribers
